Mounjaro injections for obesity contain Tirzepatide, a groundbreaking medication that targets both GLP-1 and GIP receptors to reduce appetite, regulate blood sugar, and promote significant weight loss
Even the combination regimen of anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) agents merely witness a slight increased ORR to 37% with PFS at 5.9 month (136, 175)
Journal of Orthopaedic Research, 24(5), 982-989
This means a subcutaneous injection in the abdomen can, and likely does, influence tissues throughout the body, including a damaged ankle
doi: 10.1016/j.bcp.2024.116161 28 HuangJZhangXZhangHLiYHuangHLiZet al
Central nervous system control of food intake and body weight